Literature DB >> 6256414

Various enzyme activities in muscle and other organs of dystrophic mice.

T Aoyagi, T Wada, F Kojima, M Nagai, H Umezawa.   

Abstract

To elucidate the metabolic abnormality of musclar dystrophy, 27 kinds of enzyme activity in various organs of control and dystrophic mice were examined. The organs examined included muscle, bone, heart, testis, uterus, spleen, thymus, submaxillary gland, stomach, pancreas, liver, kidney, brain, and lung. The activities of 14 different aminopeptidases, 5 endopeptidases, 4 glycosidases, phosphatase, esterase, and ribonuclease were measured. Most of the enzyme activities were significantly elevated in muscles and bones of dystrophic mice. These organs were similar in their patterns of enzyme abnormality. Among the 14 kinds of aminopeptidase activity studied, the degree of increased activity was greater for the aminopeptidases (AP):Ala-AP, Leu-AP, Met-AP, Phe-AP, Trp-AP, Gly-Pro-Leu-AP. In addition to aminopeptidases, there were significant increases in activities of chymotrypsinlike enzyme, cathepsin C, cathepsin D, several glycosidases and neutral ribonuclease in the muscles of dystrophic mice. Similarly increased enzyme activity was also observed in organs other than muscle and bone. Furthermore, protein content in most organs was higher in dystrophic mice than in those of control mice. These abnormalities were seen in both males and females. The present results suggest that there are extensive abnormalities in the protein metabolism in dystrophic mice. It seems therefore that the therapeutic approach to muscular dystrophy should be studies not only from the well-known abnormality of intramuscular endopeptidases, but from other aspects as well.

Entities:  

Mesh:

Substances:

Year:  1981        PMID: 6256414      PMCID: PMC371571          DOI: 10.1172/JCI110032

Source DB:  PubMed          Journal:  J Clin Invest        ISSN: 0021-9738            Impact factor:   14.808


  17 in total

1.  The inhibition by pepstatin of cathepsin D and autolysis of dystrophic muscle.

Authors:  A A Iodice
Journal:  Life Sci       Date:  1976-11-01       Impact factor: 5.037

2.  Delayed degeneration of dystrophic and normal muscle cell cultures treated with pepstatin, leupeptin, and antipain.

Authors:  E B McGowan; S A Shafiq; A Stracher
Journal:  Exp Neurol       Date:  1976-03       Impact factor: 5.330

3.  Bestatin, an inhibitor of aminopeptidase B, produced by actinomycetes.

Authors:  H Umezawa; T Aoyagi; H Suda; M Hamada; T Takeuchi
Journal:  J Antibiot (Tokyo)       Date:  1976-01       Impact factor: 2.649

4.  Release of a plasma membrane-bound triaminopeptidase activity from mammalian cells by thermolysin.

Authors:  T Aoyagi; H Suda; M Nagai; H Tobe; J Suzuki; T Takeuchi; H Umezawa
Journal:  Biochem Biophys Res Commun       Date:  1978-01-30       Impact factor: 3.575

5.  Change of enzyme activities during the early stage of influenza virus infection.

Authors:  T Aoyagi; K Nerome; J Suzuki; T Takeuchi; H Umezawa
Journal:  Biochem Biophys Res Commun       Date:  1974-10-08       Impact factor: 3.575

6.  Effect of pepstatin on acid proteases.

Authors:  T Aoyagi; S Kunimoto; H Morishima; T Takeuchi; H Umezawa
Journal:  J Antibiot (Tokyo)       Date:  1971-10       Impact factor: 2.649

7.  Serine protease in mice with hereditary muscular dystrophy.

Authors:  Y Sanada; N Yasogawa; N Katunuma
Journal:  J Biochem       Date:  1978-01       Impact factor: 3.387

8.  Leupeptin, a protease inhibitor, decreases protein degradation in normal and diseased muscles.

Authors:  P Libby; A L Goldberg
Journal:  Science       Date:  1978-02-03       Impact factor: 47.728

9.  Aminopeptidase activities on the surface of mammalian cells.

Authors:  T Aoyagi; H Suda; M Nagai; K Ogawa; J Suzuki
Journal:  Biochim Biophys Acta       Date:  1976-11-08

10.  Muscular dystrophy: inhibition of degeneration in vivo with protease inhibitors.

Authors:  A Stracher; E B McGowan; S A Shafiq
Journal:  Science       Date:  1978-04-07       Impact factor: 47.728

View more
  5 in total

1.  Esterase profile of human masseter muscle.

Authors:  S Kirkeby; D Moe; H Vilmann
Journal:  J Anat       Date:  1988-04       Impact factor: 2.610

2.  Deficiency of kallikrein-like enzyme activities in cerebral tissue of patients with Alzheimer's disease.

Authors:  T Aoyagi; T Wada; M Nagai; F Kojima; S Harada; T Takeuchi; H Takahashi; K Hirokawa; T Tsumita
Journal:  Experientia       Date:  1990-01-15

3.  Deficiency of fibrinolytic enzyme activities in the serum of patients with Alzheimer-type dementia.

Authors:  T Aoyagi; T Wada; F Kojima; M Nagai; S Harada; T Takeuchi; K Isse; M Ogura; M Hamamoto; K Tanaka
Journal:  Experientia       Date:  1992-07-15

4.  Dexamethasone induced alterations in the levels of proteases involved in blood pressure homeostasis and blood coagulation in rats.

Authors:  S Rajashree; R Puvanakrishnan
Journal:  Mol Cell Biochem       Date:  1999-07       Impact factor: 3.396

5.  Alterations of dystrophin-associated glycoproteins in the heart lacking dystrophin or dystrophin and utrophin.

Authors:  Katharine M Sharpe; Monica D Premsukh; DeWayne Townsend
Journal:  J Muscle Res Cell Motil       Date:  2013-10-06       Impact factor: 2.698

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.